Article

Key clinical point: Atopic dermatitis (AD) negatively affects the prognosis, quality of life (QoL), and work life in young workers with occupational contact dermatitis (OCD).

Major finding: The prevalence of previously diagnosed AD was 41.8%. A higher proportion of workers with vs without AD experienced eczema during the last 3 months of response submission (adjusted odds ratio [aOR] 1.7; P < .001) and reported that OCD had negatively affected their choice of jobs and occupations (aOR 1.4; P < .001). Workers with vs without AD had significantly higher mean scores in the emotions (P < .01) and symptoms (P < .001) subscales of the Skindex-29 assessment of QoL.

Study details: Findings are from a retrospective questionnaire-based study including 2392 workers age < 35 years with OCD who answered a question about being previously diagnosed with AD.

Disclosures: This study was funded by the Danish Working Environment Research Fund. The authors declared no conflicts of interest.

Source: Dietz JB et al. Impact of atopic dermatitis on occupational contact dermatitis among young people: A retrospective cohort study. Contact Dermatitis. 2023 (Sep 26). doi: 10.1111/cod.14426

Key clinical point: Atopic dermatitis (AD) negatively affects the prognosis, quality of life (QoL), and work life in young workers with occupational contact dermatitis (OCD).

Major finding: The prevalence of previously diagnosed AD was 41.8%. A higher proportion of workers with vs without AD experienced eczema during the last 3 months of response submission (adjusted odds ratio [aOR] 1.7; P < .001) and reported that OCD had negatively affected their choice of jobs and occupations (aOR 1.4; P < .001). Workers with vs without AD had significantly higher mean scores in the emotions (P < .01) and symptoms (P < .001) subscales of the Skindex-29 assessment of QoL.

Study details: Findings are from a retrospective questionnaire-based study including 2392 workers age < 35 years with OCD who answered a question about being previously diagnosed with AD.

Disclosures: This study was funded by the Danish Working Environment Research Fund. The authors declared no conflicts of interest.

Source: Dietz JB et al. Impact of atopic dermatitis on occupational contact dermatitis among young people: A retrospective cohort study. Contact Dermatitis. 2023 (Sep 26). doi: 10.1111/cod.14426

Key clinical point: Atopic dermatitis (AD) negatively affects the prognosis, quality of life (QoL), and work life in young workers with occupational contact dermatitis (OCD).

Major finding: The prevalence of previously diagnosed AD was 41.8%. A higher proportion of workers with vs without AD experienced eczema during the last 3 months of response submission (adjusted odds ratio [aOR] 1.7; P < .001) and reported that OCD had negatively affected their choice of jobs and occupations (aOR 1.4; P < .001). Workers with vs without AD had significantly higher mean scores in the emotions (P < .01) and symptoms (P < .001) subscales of the Skindex-29 assessment of QoL.

Study details: Findings are from a retrospective questionnaire-based study including 2392 workers age < 35 years with OCD who answered a question about being previously diagnosed with AD.

Disclosures: This study was funded by the Danish Working Environment Research Fund. The authors declared no conflicts of interest.

Source: Dietz JB et al. Impact of atopic dermatitis on occupational contact dermatitis among young people: A retrospective cohort study. Contact Dermatitis. 2023 (Sep 26). doi: 10.1111/cod.14426

Key clinical point: Xyloglucan and pea protein (XG-PP)-based topical treatment shows safety and efficacy outcomes comparable with those of hydrocortisone in pediatric patients with atopic dermatitis (AD).

Major finding: At 8 and 15 days of treatment, both XG-PP and hydrocortisone led to significant decreases in the AD Severity Index (ADSI) score (all P = .00001). Both treatment arms showed similar decrease in ADSI scores at 8 (P = .91) and 15 (P = .92) days. No adverse events were reported in the XG-PP treatment arm.

Study details: Findings are from a prospective multicenter study including 42 pediatric patients with mild-to-moderate AD (age 6 months-12 years) who were randomly assigned to receive either topical XG-PP-based cream or hydrocortisone twice daily for 14 consecutive days.

Disclosures: This study was sponsored by Novintethical Pharma SA. The authors declared no conflicts of interest.

Source: Sowlati M et al. Efficacy and tolerability of a novel topical treatment containing pea protein and xyloglucan in the management of atopic dermatitis in children: A prospective, multicenter clinical study. Dermatol Ther (Heidelb). 2023 (Sep 23). doi: 10.1007/s13555-023-01035-6

Key clinical point: Xyloglucan and pea protein (XG-PP)-based topical treatment shows safety and efficacy outcomes comparable with those of hydrocortisone in pediatric patients with atopic dermatitis (AD).

Major finding: At 8 and 15 days of treatment, both XG-PP and hydrocortisone led to significant decreases in the AD Severity Index (ADSI) score (all P = .00001). Both treatment arms showed similar decrease in ADSI scores at 8 (P = .91) and 15 (P = .92) days. No adverse events were reported in the XG-PP treatment arm.

Study details: Findings are from a prospective multicenter study including 42 pediatric patients with mild-to-moderate AD (age 6 months-12 years) who were randomly assigned to receive either topical XG-PP-based cream or hydrocortisone twice daily for 14 consecutive days.

Disclosures: This study was sponsored by Novintethical Pharma SA. The authors declared no conflicts of interest.

Source: Sowlati M et al. Efficacy and tolerability of a novel topical treatment containing pea protein and xyloglucan in the management of atopic dermatitis in children: A prospective, multicenter clinical study. Dermatol Ther (Heidelb). 2023 (Sep 23). doi: 10.1007/s13555-023-01035-6

Key clinical point: Xyloglucan and pea protein (XG-PP)-based topical treatment shows safety and efficacy outcomes comparable with those of hydrocortisone in pediatric patients with atopic dermatitis (AD).

Major finding: At 8 and 15 days of treatment, both XG-PP and hydrocortisone led to significant decreases in the AD Severity Index (ADSI) score (all P = .00001). Both treatment arms showed similar decrease in ADSI scores at 8 (P = .91) and 15 (P = .92) days. No adverse events were reported in the XG-PP treatment arm.

Study details: Findings are from a prospective multicenter study including 42 pediatric patients with mild-to-moderate AD (age 6 months-12 years) who were randomly assigned to receive either topical XG-PP-based cream or hydrocortisone twice daily for 14 consecutive days.

Disclosures: This study was sponsored by Novintethical Pharma SA. The authors declared no conflicts of interest.

Source: Sowlati M et al. Efficacy and tolerability of a novel topical treatment containing pea protein and xyloglucan in the management of atopic dermatitis in children: A prospective, multicenter clinical study. Dermatol Ther (Heidelb). 2023 (Sep 23). doi: 10.1007/s13555-023-01035-6

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk for multiple neuropsychiatric conditions; however, the risk profiles for specific neuropsychiatric conditions differ with AD severity.

Major finding: Adults with AD (of any severity level) vs without AD had a higher risk for anxiety (adjusted hazard ratio [aHR] 1.14, 95% CI 1.13-1.15), depression (aHR 1.14, 95% CI 1.13-1.15), and obsessive-compulsive disorder (aHR 1.48, 95% CI 1.38-1.58); the risk for autism increased in patients with mild (aHR 1.55; 95% CI 1.26-1.89) and moderate (aHR 1.40; 95% CI 1.07-1.83) AD and that for attention-deficit/hyperactivity disorder increased in those with mild AD (aHR 1.27; 95% CI 1.03-1.55].

Study details: This population-based cohort study included 625,083 adults with AD who were matched with 2,678,888 control adults without AD.

Disclosures: This study was supported by a contract from Pfizer, Inc. Some authors declared receiving research or fellowship funding or consultation honoraria from various sources, including Pfizer. AR Lemeshow declared being an employee of Pfizer.

Source: Wan J et al. Neuropsychiatric disorders in adults with atopic dermatitis: A population-based cohort study. J Eur Acad Dermatol Venereol. 2023 (Sep 20). doi: 10.1111/jdv.19518

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk for multiple neuropsychiatric conditions; however, the risk profiles for specific neuropsychiatric conditions differ with AD severity.

Major finding: Adults with AD (of any severity level) vs without AD had a higher risk for anxiety (adjusted hazard ratio [aHR] 1.14, 95% CI 1.13-1.15), depression (aHR 1.14, 95% CI 1.13-1.15), and obsessive-compulsive disorder (aHR 1.48, 95% CI 1.38-1.58); the risk for autism increased in patients with mild (aHR 1.55; 95% CI 1.26-1.89) and moderate (aHR 1.40; 95% CI 1.07-1.83) AD and that for attention-deficit/hyperactivity disorder increased in those with mild AD (aHR 1.27; 95% CI 1.03-1.55].

Study details: This population-based cohort study included 625,083 adults with AD who were matched with 2,678,888 control adults without AD.

Disclosures: This study was supported by a contract from Pfizer, Inc. Some authors declared receiving research or fellowship funding or consultation honoraria from various sources, including Pfizer. AR Lemeshow declared being an employee of Pfizer.

Source: Wan J et al. Neuropsychiatric disorders in adults with atopic dermatitis: A population-based cohort study. J Eur Acad Dermatol Venereol. 2023 (Sep 20). doi: 10.1111/jdv.19518

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk for multiple neuropsychiatric conditions; however, the risk profiles for specific neuropsychiatric conditions differ with AD severity.

Major finding: Adults with AD (of any severity level) vs without AD had a higher risk for anxiety (adjusted hazard ratio [aHR] 1.14, 95% CI 1.13-1.15), depression (aHR 1.14, 95% CI 1.13-1.15), and obsessive-compulsive disorder (aHR 1.48, 95% CI 1.38-1.58); the risk for autism increased in patients with mild (aHR 1.55; 95% CI 1.26-1.89) and moderate (aHR 1.40; 95% CI 1.07-1.83) AD and that for attention-deficit/hyperactivity disorder increased in those with mild AD (aHR 1.27; 95% CI 1.03-1.55].

Study details: This population-based cohort study included 625,083 adults with AD who were matched with 2,678,888 control adults without AD.

Disclosures: This study was supported by a contract from Pfizer, Inc. Some authors declared receiving research or fellowship funding or consultation honoraria from various sources, including Pfizer. AR Lemeshow declared being an employee of Pfizer.

Source: Wan J et al. Neuropsychiatric disorders in adults with atopic dermatitis: A population-based cohort study. J Eur Acad Dermatol Venereol. 2023 (Sep 20). doi: 10.1111/jdv.19518

Key clinical point: Both ciclosporin and methotrexate were effective against severe atopic dermatitis (AD) in children, but ciclosporin resulted in a more rapid response whereas methotrexate led to more sustained disease control even after treatment discontinuation.

Major finding: At 12 weeks, a significantly higher proportion of patients achieved 50% improvement in Objective Severity Scoring of Atopic Dermatitis scores (o-SCORAD-50) with ciclosporin vs methotrexate (P = .012). However, at 60 weeks, the proportion of patients who achieved o-SCORAD-50 was higher with methotrexate vs ciclosporin (P = .022). Adverse event rates were comparable in both groups.

Study details: The TREatment of severe Atopic Eczema Trial included 103 children with severe AD (age 2-16 years) who were unresponsive to topical treatments and were randomly assigned to receive ciclosporin or methotrexate.

Disclosures: This study was funded by the UK Medical Research Council/National Institute for Health Research (NIHR). Some authors, including the lead author, declared receiving consulting fees, advisory fees, or research funding from various sources, including UK NIHR.

Source: Flohr C et al and the TREAT Trial Investigators. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): A multicentre, parallel group, assessor-blinded clinical trial. Br J Dermatol. 2023 (Sep 19). doi: 10.1093/bjd/ljad281

Key clinical point: Both ciclosporin and methotrexate were effective against severe atopic dermatitis (AD) in children, but ciclosporin resulted in a more rapid response whereas methotrexate led to more sustained disease control even after treatment discontinuation.

Major finding: At 12 weeks, a significantly higher proportion of patients achieved 50% improvement in Objective Severity Scoring of Atopic Dermatitis scores (o-SCORAD-50) with ciclosporin vs methotrexate (P = .012). However, at 60 weeks, the proportion of patients who achieved o-SCORAD-50 was higher with methotrexate vs ciclosporin (P = .022). Adverse event rates were comparable in both groups.

Study details: The TREatment of severe Atopic Eczema Trial included 103 children with severe AD (age 2-16 years) who were unresponsive to topical treatments and were randomly assigned to receive ciclosporin or methotrexate.

Disclosures: This study was funded by the UK Medical Research Council/National Institute for Health Research (NIHR). Some authors, including the lead author, declared receiving consulting fees, advisory fees, or research funding from various sources, including UK NIHR.

Source: Flohr C et al and the TREAT Trial Investigators. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): A multicentre, parallel group, assessor-blinded clinical trial. Br J Dermatol. 2023 (Sep 19). doi: 10.1093/bjd/ljad281

Key clinical point: Both ciclosporin and methotrexate were effective against severe atopic dermatitis (AD) in children, but ciclosporin resulted in a more rapid response whereas methotrexate led to more sustained disease control even after treatment discontinuation.

Major finding: At 12 weeks, a significantly higher proportion of patients achieved 50% improvement in Objective Severity Scoring of Atopic Dermatitis scores (o-SCORAD-50) with ciclosporin vs methotrexate (P = .012). However, at 60 weeks, the proportion of patients who achieved o-SCORAD-50 was higher with methotrexate vs ciclosporin (P = .022). Adverse event rates were comparable in both groups.

Study details: The TREatment of severe Atopic Eczema Trial included 103 children with severe AD (age 2-16 years) who were unresponsive to topical treatments and were randomly assigned to receive ciclosporin or methotrexate.

Disclosures: This study was funded by the UK Medical Research Council/National Institute for Health Research (NIHR). Some authors, including the lead author, declared receiving consulting fees, advisory fees, or research funding from various sources, including UK NIHR.

Source: Flohr C et al and the TREAT Trial Investigators. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): A multicentre, parallel group, assessor-blinded clinical trial. Br J Dermatol. 2023 (Sep 19). doi: 10.1093/bjd/ljad281

Key clinical point: Compared with children without atopic dermatitis (AD), those with AD are significantly more likely to have positive patch tests (PPT) and respond to ≥1 allergen on patch testing.

Major finding: Children with vs without AD were significantly more likely to have a longer duration of dermatitis (P < .0001), >1 PPT result (P = .005), a greater number of PPT overall (P = .012), and a more generalized distribution of dermatitis (P = .001) as well as PPT to bacitracin (P = .030), carba mix (diphenylguanidine, zinc dibutyldithiocarbamate, and zinc diethyldithiocarbamate) (P = .025), and cocamidopropyl betaine (P = .0007).

Study details: This retrospective case-control study included 615 children with AD and 297 children without AD.

Disclosures: This study was supported by the Dermatology Foundation, Evanston, IL. The authors declared no conflicts of interest.

Source: Johnson H et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study. J Am Acad Dermatol. 2023;89(5):1007-1014 (Sep 25). doi: 10.1016/j.jaad.2023.06.048

Key clinical point: Compared with children without atopic dermatitis (AD), those with AD are significantly more likely to have positive patch tests (PPT) and respond to ≥1 allergen on patch testing.

Major finding: Children with vs without AD were significantly more likely to have a longer duration of dermatitis (P < .0001), >1 PPT result (P = .005), a greater number of PPT overall (P = .012), and a more generalized distribution of dermatitis (P = .001) as well as PPT to bacitracin (P = .030), carba mix (diphenylguanidine, zinc dibutyldithiocarbamate, and zinc diethyldithiocarbamate) (P = .025), and cocamidopropyl betaine (P = .0007).

Study details: This retrospective case-control study included 615 children with AD and 297 children without AD.

Disclosures: This study was supported by the Dermatology Foundation, Evanston, IL. The authors declared no conflicts of interest.

Source: Johnson H et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study. J Am Acad Dermatol. 2023;89(5):1007-1014 (Sep 25). doi: 10.1016/j.jaad.2023.06.048

Key clinical point: Compared with children without atopic dermatitis (AD), those with AD are significantly more likely to have positive patch tests (PPT) and respond to ≥1 allergen on patch testing.

Major finding: Children with vs without AD were significantly more likely to have a longer duration of dermatitis (P < .0001), >1 PPT result (P = .005), a greater number of PPT overall (P = .012), and a more generalized distribution of dermatitis (P = .001) as well as PPT to bacitracin (P = .030), carba mix (diphenylguanidine, zinc dibutyldithiocarbamate, and zinc diethyldithiocarbamate) (P = .025), and cocamidopropyl betaine (P = .0007).

Study details: This retrospective case-control study included 615 children with AD and 297 children without AD.

Disclosures: This study was supported by the Dermatology Foundation, Evanston, IL. The authors declared no conflicts of interest.

Source: Johnson H et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: A multicenter retrospective case-control study. J Am Acad Dermatol. 2023;89(5):1007-1014 (Sep 25). doi: 10.1016/j.jaad.2023.06.048

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).

Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581

Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).

Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581

Key clinical point: The combination of oral metronomic capecitabine and pyrotinib showed acceptable efficacy and tolerable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: Patients receiving metronomic capecitabine + pyrotinib had an objective response rate of 34.7% and a clinical benefit rate of 81.6%, with 4.1% and 30.6% of patients achieving complete and partial responses, respectively, which lasted for ≥ 24 weeks. The most common grade 3 adverse events were hand-foot syndrome (12.2%), diarrhea (12.2%), vomiting (4.1%), and nausea (2.0%).

Study details: Findings are from a prospective, single-arm phase 2 trial including 49 patients with HER2+ metastatic BC who received 500 mg oral metronomic capecitabine 3 times per day and 400 mg pyrotinib per day.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: He M, Liu J, et al. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial. Breast. 2023;72:105381 (Sep 19). doi: 10.1016/j.breast.2023.103581

Key clinical point: First-line therapy with palbociclib plus an aromatase inhibitor (AI) vs only AI improved survival outcomes in elderly patients (age ≥75 years) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC).

Major finding: Patients receiving palbociclib + AI combination therapy vs only AI had a significantly improved overall survival (hazard ratio 0.66; P = .0007), real-world progression-free survival (hazard ratio 0.72; P = .0021) and prolonged time to receiving chemotherapy (hazard ratio 0.69; P = .0014).

Study details: This sub-analysis of the retrospective observational P-REALITY X cohort study included 961 patients with HR+/HER2− metastatic BC who were age ≥ 75 years and received either palbociclib + AI (32.6%) or only AI (67.4%) as first-line therapy.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer. The other authors declared receiving research grants, consulting or advisory fees, honoraria, or sponsorship for research from Pfizer and other sources.

Source: Brufsky A et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751 (Sep 28). doi: 10.3389/fonc.2023.1237751

Key clinical point: First-line therapy with palbociclib plus an aromatase inhibitor (AI) vs only AI improved survival outcomes in elderly patients (age ≥75 years) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC).

Major finding: Patients receiving palbociclib + AI combination therapy vs only AI had a significantly improved overall survival (hazard ratio 0.66; P = .0007), real-world progression-free survival (hazard ratio 0.72; P = .0021) and prolonged time to receiving chemotherapy (hazard ratio 0.69; P = .0014).

Study details: This sub-analysis of the retrospective observational P-REALITY X cohort study included 961 patients with HR+/HER2− metastatic BC who were age ≥ 75 years and received either palbociclib + AI (32.6%) or only AI (67.4%) as first-line therapy.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer. The other authors declared receiving research grants, consulting or advisory fees, honoraria, or sponsorship for research from Pfizer and other sources.

Source: Brufsky A et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751 (Sep 28). doi: 10.3389/fonc.2023.1237751

Key clinical point: First-line therapy with palbociclib plus an aromatase inhibitor (AI) vs only AI improved survival outcomes in elderly patients (age ≥75 years) with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (BC).

Major finding: Patients receiving palbociclib + AI combination therapy vs only AI had a significantly improved overall survival (hazard ratio 0.66; P = .0007), real-world progression-free survival (hazard ratio 0.72; P = .0021) and prolonged time to receiving chemotherapy (hazard ratio 0.69; P = .0014).

Study details: This sub-analysis of the retrospective observational P-REALITY X cohort study included 961 patients with HR+/HER2− metastatic BC who were age ≥ 75 years and received either palbociclib + AI (32.6%) or only AI (67.4%) as first-line therapy.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer. The other authors declared receiving research grants, consulting or advisory fees, honoraria, or sponsorship for research from Pfizer and other sources.

Source: Brufsky A et al. Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751 (Sep 28). doi: 10.3389/fonc.2023.1237751

Key clinical point: Receptor profiles and the presence of extracranial visceral metastases were significant predictors of prognosis in patients with metastatic breast cancer (BC) who had brain metastases and underwent stereotactic radiosurgery (SRS).

Major finding: The median overall survival (OS) was 14.8 months for the entire cohort. OS outcomes worsened in patients with estrogen receptor-negative (ER−)/human epidermal growth factor receptor 2-negative (HER2−) BC (hazard ratio [HR] 2.00; 95% CI 1.09-3.67) but were better in those with ER+/HER2+ BC (HR 0.43; 95% CI 0.19-0.96). The presence of extracranial visceral metastases (HR 2.90; 95% CI 1.53-5.50) was also associated with poor survival outcomes.

Study details: Findings are from a retrospective analysis of a cohort including 149 patients with metastatic breast cancer and brain metastases underwent received SRS.

Disclosures: This study was supported by Lundbeck Foundation, Copenhagen. The authors declared no conflicts of interest.

Source: Depner JF et al. Treating brain metastases in metastatic breast cancer: Outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis. Acta Oncol. 2023 (Sep 26). doi: 10.1080/0284186X.2023.2260942

Key clinical point: Receptor profiles and the presence of extracranial visceral metastases were significant predictors of prognosis in patients with metastatic breast cancer (BC) who had brain metastases and underwent stereotactic radiosurgery (SRS).

Major finding: The median overall survival (OS) was 14.8 months for the entire cohort. OS outcomes worsened in patients with estrogen receptor-negative (ER−)/human epidermal growth factor receptor 2-negative (HER2−) BC (hazard ratio [HR] 2.00; 95% CI 1.09-3.67) but were better in those with ER+/HER2+ BC (HR 0.43; 95% CI 0.19-0.96). The presence of extracranial visceral metastases (HR 2.90; 95% CI 1.53-5.50) was also associated with poor survival outcomes.

Study details: Findings are from a retrospective analysis of a cohort including 149 patients with metastatic breast cancer and brain metastases underwent received SRS.

Disclosures: This study was supported by Lundbeck Foundation, Copenhagen. The authors declared no conflicts of interest.

Source: Depner JF et al. Treating brain metastases in metastatic breast cancer: Outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis. Acta Oncol. 2023 (Sep 26). doi: 10.1080/0284186X.2023.2260942

Key clinical point: Receptor profiles and the presence of extracranial visceral metastases were significant predictors of prognosis in patients with metastatic breast cancer (BC) who had brain metastases and underwent stereotactic radiosurgery (SRS).

Major finding: The median overall survival (OS) was 14.8 months for the entire cohort. OS outcomes worsened in patients with estrogen receptor-negative (ER−)/human epidermal growth factor receptor 2-negative (HER2−) BC (hazard ratio [HR] 2.00; 95% CI 1.09-3.67) but were better in those with ER+/HER2+ BC (HR 0.43; 95% CI 0.19-0.96). The presence of extracranial visceral metastases (HR 2.90; 95% CI 1.53-5.50) was also associated with poor survival outcomes.

Study details: Findings are from a retrospective analysis of a cohort including 149 patients with metastatic breast cancer and brain metastases underwent received SRS.

Disclosures: This study was supported by Lundbeck Foundation, Copenhagen. The authors declared no conflicts of interest.

Source: Depner JF et al. Treating brain metastases in metastatic breast cancer: Outcomes after stereotactic radiosurgery examined in a retrospective, single-center cohort analysis. Acta Oncol. 2023 (Sep 26). doi: 10.1080/0284186X.2023.2260942

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266

Key clinical point: Surgical removal of the primary tumor failed to prolong survival and may not be necessary in patients with de novo metastatic breast cancer (BC).

Major finding: In women with de novo metastatic BC, primary breast tumor surgery vs no surgery improved the local progression-free survival outcomes (hazard ratio [HR] 0.37; 95% CI 0.19-0.74) but not the overall survival (HR 0.93; 95% CI 0.76-1.14).

Study details: Findings are from a meta-analysis of five randomized controlled trials including 1381 patients with de novo metastatic BC, of whom 49.6% underwent primary breast tumor surgery.

Disclosures: This study did not receive any specific funding. Three authors declared having advisory roles, serving as consultants, or receiving speaker fees, consulting fees, or unrelated research grants from various sources.

Source: Villacampa G et al. Impact of primary breast surgery on overall survival of patients with de novo metastatic breast cancer: A systematic review and meta-analysis. Oncologist. 2023 (Sep 12). doi: 10.1093/oncolo/oyad266